This inventor holds 1 USPTO granted patent. Top assignee: Beckman Research Institute, City of Hope. Active years: 2025.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2025
Title: The Innovations of Michael Kahn
Introduction
Michael Kahn is an accomplished inventor based in Monrovia, California. He has made significant contributions to the field of pharmaceutical sciences, particularly in the development of compounds that target specific signaling pathways in the body. His work is crucial for advancing treatments for various disorders.
Latest Patents
One of Michael Kahn's notable patents is titled "Substituted pyrazino[2,1-c][1,2,4]triazines as Wnt/CBP/catenin signaling pathway inhibitors." This patent discloses compounds of formula (Ia), (Ib), or (Ic), along with their pharmaceutically acceptable salts or stereoisomers. The patent outlines methods for modulating CREB binding protein (CBP)/catenin signaling pathway activity, which is essential for treating CBP/β-catenin mediated disorders. Michael Kahn holds 1 patent in this area.
Career Highlights
Michael Kahn is associated with City of Hope, a prominent research and treatment center. His work there focuses on innovative approaches to combat diseases through targeted therapies. His expertise in the field has positioned him as a valuable asset in the ongoing research efforts at the institution.
Collaborations
[This section has been skipped due to space constraints.]
Conclusion
Michael Kahn's contributions to the field of pharmaceutical sciences through his innovative patent work exemplify the impact of targeted therapies in modern medicine. His ongoing efforts at City of Hope continue to pave the way for advancements in treating complex disorders.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile